Search
Viking Therapeutics Inc
VKTXAdd to Watchlist
30.380USD
+0.090+0.30%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
3.52BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Viking Therapeutics Inc is 8.50, ranking 106 out of 389 in the Biotechnology & Medical Research industry. The average price target is 100.50, with a high of 125.00 and a low of 36.00.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
93.222
Target Price
+206.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Viking Therapeutics Inc
VKTX
20
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Viking Therapeutics Inc's price target?
Analysts forecast that Viking Therapeutics Inc's price target is USD 100.50, with the highest forecast at USD 125.00 and the lowest forecast at USD 36.00.
How have Viking Therapeutics IncVKTX's recent earnings per share performed?
The market expectation was USD -1.37, while Viking Therapeutics IncVKTX's earnings per share (EPS) for the previous quarter was USD -1.38. EPS for the next quarter is expected at USD -1.22.
What is the analyst rating for Viking Therapeutics Inc?
Based on the ratings of Viking Therapeutics Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
